Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Press Releases

Press Releases

All Releases
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the 2017 Southern California Investor Conference in Newport Beach on Thursday, August 24th
Aug 17, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Initiation of the Registrational Phase 3 Trial of Qapzola™ (apaziquone) in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Aug 14, 2017
PDF 18.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Pipeline Update
Aug 3, 2017
PDF 41.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Completion of Enrollment in the Phase 3 Pivotal Study (ADVANCE) of ROLONTIS™ (eflapegrastim), a Novel Long-Acting GCSF
Aug 1, 2017
PDF 17.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Second Quarter 2017 Financial Results Teleconference and Webcast
Jul 27, 2017
PDF 14.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Results of a Combination Study of FOLOTYN® (pralatrexate injection) Plus Romidepsin Presented at the 14th International Conference on Malignant Lymphoma (14-ICML) Meeting
Jun 19, 2017
PDF 21.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Three Abstracts of Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017
Jun 2, 2017
PDF 15.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2017 Global Healthcare Conference on June 6th
May 30, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2017 Health Care Conference on May 17
May 16, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update
May 2, 2017
PDF 38.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the 42nd Annual Deutsche Bank Health Care Conference on May 4
Apr 27, 2017
PDF 13.9 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces First Quarter 2017 Financial Results Teleconference and Webcast
Apr 25, 2017
PDF 14.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS™ (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting
Apr 4, 2017
PDF 16.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Three Abstracts on ROLONTIS™ (eflapegrastim) and BELEODAQ® (belinostat) for injection at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C., April 1-5, 2017
Mar 31, 2017
PDF 15.1 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
Mar 30, 2017
PDF 17.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results and Pipeline Update
Mar 8, 2017
PDF 43.1 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Teleconference and Webcast
Mar 1, 2017
PDF 14.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the 2017 RBC Capital Markets Global Healthcare Conference on February 23rd
Feb 16, 2017
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
Dec 8, 2016
PDF 61.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Survival Advantage in a Case Match Control Analysis of the PROPEL Study with FOLOTYN® (pralatrexate injection) at the 58th Annual Meeting of the American Society of Hematology (ASH)
Dec 6, 2016
PDF 18.6 KB Add to Briefcase
Showing 1-20 of 712 Page: 1 2 3 4 5 ... 36  Next 20
Add to Briefcase = add release to Briefcase

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
9.40
Change:
- 0.05
Day High:
9.51
Day Low:
9.32
Volume:
1,166,850
4:00 PM ET on Aug 18, 2017
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR